Dicloreum Actigel: Therapeutic Uses

Dicloreum Actigel is authorized for application to the skin to provide symptomatic relief for certain painful, inflammatory conditions. Its use is generally confined to conditions that affect the musculoskeletal system and is applied directly to the affected area.

This topical product is used to treat localized pain and inflammation associated with recent soft-tissue injuries, such as strains, sprains, bruises, and other forms of trauma involving the muscles and joints. It is also indicated for localized forms of soft-tissue rheumatism, including conditions like tendinitis and bursitis. The benefit of using this topical formulation is the localized delivery of the active substance, which helps in the reduction of pain at the application site.

Eligibility Map: Who can and cannot use Dicloreum Actigel — Official Regulatory Information

Eligibility scope

• Populations for whom use is allowed (as stated in label): Adults (aged 18 and over) and Adolescents (aged 14 and over) for specific post-traumatic pain conditions.
• Populations for whom use is not recommended (if applicable): Concomitant use with oral NSAIDs is not recommended. Use is advised against in patients with advanced renal disease or severe heart failure, unless the benefits outweigh the risks.
• Populations for whom use is contraindicated: Children under 14 years of age; patients with a known hypersensitivity to Diclofenac or other NSAIDs (including aspirin-sensitive asthma); use in the third trimester of pregnancy; and use for peri-operative pain in the setting of CABG surgery.

Age-related eligibility rules: The medicine is contraindicated in individuals under 14 years. Older adults may use the usual adult dose.

Condition-specific eligibility rules: Use is avoided in patients with severe heart failure or advanced renal impairment.

Pregnancy and lactation eligibility status (if explicitly documented): Use is contraindicated during the third trimester of pregnancy. It is restricted during the first two trimesters and while breastfeeding.

Eligibility-related restrictions: The product must only be applied to intact, non-diseased skin.

Eligibility classifications (high-level)

• Eligibility severity classification (as defined in official documents): Ranges from Absolute Contraindication (e.g., third trimester, aspirin allergy) to Conditional Use (e.g., first trimester, breastfeeding).
• Regulatory basis (EMA / FDA / etc.): The profile is grounded in the official regulatory documentation, including the SmPC and FDA Prescribing Information.
• Eligibility-context constraints (as defined in official documents): Eligibility is conditional on the patient's systemic health history and the integrity of the application site.

Resulting eligibility structure Official eligibility statements:

• The medicine is contraindicated in any patient with a history of allergic reactions to aspirin or other NSAIDs.
• Use is contraindicated in individuals under 14 years of age and during the third trimester of pregnancy.
• Application must be limited to intact skin, and use is avoided in cases of advanced kidney disease or severe heart failure.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing rules that range from absolute contraindications to conditional restrictions. This structure dictates mandatory exclusion for certain populations and conditions, thereby formalizing the eligible user base.

Interactions with other medicines and products

Due to the minimal systemic absorption of Diclofenac topical gel, the risk of clinically significant drug-drug interactions is generally low under normal conditions of use. However, official regulatory documents mandate the inclusion of interaction warnings relevant to systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for cases of increased systemic exposure.

• Prohibited and Non-Recommended Combinations: The official profile advises avoiding concurrent use with oral NSAIDs to prevent additive systemic adverse effects. Co-administration with Aspirin (analgesic doses) is generally not recommended due to the potential for an increased risk of serious gastrointestinal events.

• Pharmacodynamic Effects: Diclofenac may diminish the effects of certain medicines, including Antihypertensive Agents (such as ACE Inhibitors and ARBs) and Diuretics, potentially reducing their intended therapeutic effects. Combining the gel with Anticoagulants carries an increased risk of bleeding due to additive effects on hemostasis.

• Altered Drug Exposure: Diclofenac can increase the plasma concentration and prolong the half-lives of co-administered drugs, including Digoxin and Lithium.

• Substance and Population Notes: Use of Alcohol or Tobacco is noted to enhance the risk of gastrointestinal irritation. A specific precaution exists for elderly, volume depleted, or renally impaired patients using ACE Inhibitors or ARBs, where co-administration may result in deterioration of renal function. The regulatory label states that the use of other topical products on the same site should be avoided.

Enzymatic Blockade of Prostaglandin Synthesis

The mechanism of action centers on the non-selective inhibition of the Cyclooxygenase (COX) enzyme, primarily targeting the inducible COX-2 form, by acting as a competitive antagonist to the substrate, arachidonic acid. This initial molecular event directly suppresses the entire prostaglandin synthesis pathway, limiting the local production of Prostaglandin E2 (, PGE2).

Modulation of Local Physiological Responses

The resulting reduction in PGE2 concentration leads to a cascade of functional consequences in the affected tissue. This molecular change contributes to a decrease in vasodilation and capillary permeability, influencing local microcirculatory dynamics. This domain is crucial for achieving a localized modulation of the tissue's hyperactive response to injury.

Desensitization of Peripheral Nociceptive Signaling

The core mechanism influences the sensory nervous system peripherally. PGE2 typically sensitizes peripheral pain-sensing nerve endings (nociceptors); by reducing this sensitizing mediator, the drug raises the activation threshold of these nerves. The mechanism, therefore, modulates the local signals that contribute to amplified nociceptive transmission, with the action restricted to the application site.

How to Use Dicloreum Actigel

The administration of Dicloreum Actigel (Diclofenac Topical Gel) is governed by official instructions detailing the precise amount, frequency, and method of application for localized use. The drug is strictly for external topical application to the skin; it is not intended for ingestion or use on mucous membranes.

---

Official Dosing and Frequency

The dosage and schedule are standardized based on the gel's concentration, ensuring the correct amount of active substance is delivered to the application site.

Property	Administration Guideline
Route	Topical/Cutaneous Use only
1% Gel Dose	Apply 2 to 4 grams (g) per application (a 2.0-2.5 cm strip).
1% Gel Frequency	The gel is applied 3 or 4 times a day to the affected area.
Maximum Daily Use	Total application should not exceed 32 grams per day (in the context of approved 1% gel).

---

Application Method and Duration

To ensure proper administration, the prescribed quantity of the gel must be gently rubbed into the skin until the product is fully absorbed. The medication should only be applied to intact, non-diseased skin and must be kept away from open wounds or cuts.

Treatment with the topical gel is generally recommended for short-term use. For soft-tissue injuries, the duration of use typically should not exceed 7 days before a reassessment of the condition is necessary. Following application, the hands must be washed immediately, unless the hands are the area being treated.

Population-Specific Use

Adolescents aged 14 and over may use the standard adult dosage. The use of this topical gel formulation is not recommended for children under the age of 14 due to a lack of sufficient data on efficacy and safety in this population.

Recent Clinical Evidence

Dicloreum Actigel contains diclofenac, a non-steroidal anti-inflammatory drug (NSAID) delivered in a topical gel formulation. The use of topical diclofenac, such as the formulation in this product, is primarily investigated for localized musculoskeletal conditions. The goal of this delivery method is to achieve therapeutically relevant concentrations of the active ingredient in the underlying tissues, such as muscles and synovial fluid, while potentially minimizing systemic exposure compared to oral NSAIDs.

---

Efficacy in Acute Conditions

Clinical research, including randomized controlled trials, has examined the topical diclofenac diethylamine (DDEA) formulation for various acute conditions, such as mild-to-moderate joint and soft tissue injuries. Studies evaluating patients with conditions like ankle sprains or localized musculoskeletal pain have reported improvements in key measures like pain on movement (POM) and reductions in swelling. In trials, the application of the topical gel has been associated with greater pain reduction compared to a placebo gel.

---

Findings in Chronic Conditions

For chronic conditions, such as osteoarthritis (OA), systematic reviews and meta-analyses have consolidated evidence primarily focusing on knee OA. These analyses suggest that topical diclofenac gel is associated with significant improvements in pain relief and physical function compared to placebo, particularly over short- to mid-term periods (up to 12 weeks). The magnitude of improvement observed with topical formulations is generally comparable to that of other topical NSAID preparations.

---

Safety Profile Observations

The topical route of administration is associated with a different safety profile compared to oral NSAIDs. Data from clinical studies typically show that the majority of observed adverse events are local skin reactions, such as temporary irritation, itching, or redness at the application site. Systemic adverse events, commonly associated with oral NSAIDs (gastrointestinal or cardiovascular effects), are rarely reported with topical application due. Research indicates that low plasma concentrations are typically achieved, supporting the localized action.

Common questions about Dicloreum Actigel (FAQ)

Q: Is Dicloreum Actigel the same as other diclofenac gels?

A: Dicloreum Actigel contains diclofenac, the same active substance found in many topical products, but it uses a specific salt—diclofenac hydroxyethylpyrrolidine or diethylamine—within a distinct hydroalcoholic gel base. Official product information describes this specific formulation as being designed to support effective localized application.

Q: Can Dicloreum Actigel be applied under a bandage or wrap?

A: Regulatory warnings state that the gel should not be used with an airtight occlusive dressing. However, the product is described in official documentation as being compatible with the use of a non-occlusive bandage or wrap.

Q: Can I go out in the sun after applying Dicloreum Actigel?

A: Regulatory warnings advise that the treated skin area should not be exposed to sunlight. This is related to the officially noted risk of photosensitivity reactions (an increased skin sensitivity to light) classified as a very rare adverse event.

Q: Is there any information about long-term use of Dicloreum Actigel?

A: Official documents generally recommend using the gel for short periods of treatment. They also note that the possibility of systemic adverse effects, which are usually associated with oral NSAIDs, increases if the preparation is used over a prolonged period or on large areas.

Q: How long does the effect of Dicloreum Actigel usually last?

A: The required reapplication interval is indirectly addressed by the official administration guidelines. These guidelines recommend applying the gel to the affected area 3 or 4 times a day.

Q: Can Dicloreum Actigel be used for muscle pain?

A: Yes, according to official therapeutic indications, the product is indicated for the local treatment of painful and inflammatory conditions involving the muscles, in addition to joints, tendons, and ligaments.

Q: Can Dicloreum Actigel be used for bruising?

A: Official indications for the topical gel include the relief of pain and inflammation associated with trauma to soft tissues, such as bruises and strains.

Q: Does Dicloreum Actigel absorb into the skin or stay on the surface?

A: The product is intended for transdermal delivery, meaning the active ingredient is designed to be absorbed through the skin to act on the underlying affected tissues. Application instructions advise rubbing the gel into the skin until the product is fully absorbed.

Q: Is the research on Dicloreum Actigel widely published?

A: Official regulatory approval is based on clinical evidence, which is typically published in medical literature. This evidence includes randomized controlled trials and systematic reviews demonstrating the product's profile for localized musculoskeletal conditions.

Q: What should I do if I accidentally get Dicloreum Actigel in my eyes?

A: Official warnings state that the preparation must not be allowed to come into contact with the eyes or mucous membranes.

Q: Does Dicloreum Actigel contain alcohol or other common allergens?

A: The formulation includes isopropyl alcohol. Official documentation also lists other excipients, such as propylene glycol and hydroxybenzoates, which carry a specific regulatory warning due to their potential to cause local skin irritation or allergic reactions.

Q: Does Dicloreum Actigel have any known smell?

A: The product's official excipient list includes a fragrance as a non-medicinal ingredient within the gel formulation.

Q: Are there specific areas of the body where Dicloreum Actigel should not be applied?

A: Application must be strictly restricted to intact, non-diseased skin. It must be kept away from open wounds, cuts, eyes, and mucous membranes.

Q: What happens if someone accidentally uses too much Dicloreum Actigel?

A: Due to the low amount of active substance absorbed into the body when applied topically, official documents state that an overdose is considered very unlikely. In the rare case of accidental ingestion, official documents reference general measures for treating NSAID poisoning.

Q: Can Dicloreum Actigel affect kidney function when used topically?

A: While the systemic risk is low compared to oral NSAIDs, the possibility of systemic adverse effects, including kidney disorders, is noted. This risk may increase if the gel is used on large skin areas or over a prolonged period.

Q: What color is the Dicloreum Actigel formula?

A: Diclofenac topical gel formulations are typically described in their official documentation as a clear, transparent, and colorless to slightly yellow gel.

Q: Are there non-medicinal ingredients in Dicloreum Actigel that are important to know?

A: Official documents list excipients such as propylene glycol and methyl/propyl hydroxybenzoates. These ingredients carry specific warnings in official documentation for their potential to cause localized skin irritation or allergic reactions.

Q: Why is the active ingredient diclofenac commonly used in topical products?

A: The topical route is used to allow the active ingredient to reach high concentrations in the localized tissues, such as joints and muscles, which are the site of pain and inflammation. This targeted action is intended to maintain lower concentrations in the bloodstream compared to oral administration.

Q: What types of injuries is Dicloreum Actigel typically recommended for in sports medicine?

A: The official indications cover trauma to the tendons, ligaments, muscles, and joints, which includes common sports-related conditions such as sprains, strains, and bruises.

Q: Can Dicloreum Actigel be used on the face?

A: The product is intended for external topical application to the skin, but official warnings state that the preparation must not be allowed to come into contact with the eyes or mucous membranes.

Q: Do official sources describe Dicloreum Actigel as having good local tolerability?

A: Official safety data indicates that the majority of observed adverse events are localized skin reactions at the application site. These include temporary irritation, itching, or redness.

Q: Is Dicloreum Actigel typically used for acute or chronic conditions?

A: The product is officially indicated for both acute conditions (like recent trauma, sprains, and strains) and some chronic conditions (such as localized osteoarthritis). However, regulatory guidelines generally recommend use for short periods of treatment.

How to Store and Dispose of Dicloreum Actigel (Diclofenac Diethylamine Gel)

Storage and disposal must strictly follow regulatory guidance to maintain product integrity and environmental safety.

Storage Requirements

• Temperature: Store the gel at or below 25°C (or 20 C to 25 C for similar products) and do not freeze it.
• Protection: Store the product in its original tube to protect from light and keep the container tightly closed.
• Child Safety: The gel must be kept out of the reach of children. Children should also be prevented from contacting treated skin areas.
• Stability: Once opened, the gel's stability period is limited; dispose of any remaining gel 12 months after first opening.

Disposal and Handling

• Fire Hazard: Treated fabric materials are easily flammable; do not smoke or go near naked flames after application.
• Waste: Dispose of all unused or expired product in accordance with local requirements. The gel must not be thrown into wastewater as diclofenac poses a risk to the aquatic environment.